Login
Home / ASCLF : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Ascletis Pharma Inc.

$1.2 -$0.29 (-19.46%)
OTC · 14 Sep 2026 13:30 UTC
Previous Close
$1.21
Day Range
$1.2 - $1.2
Year Range
$1.07$2.5
Market Cap
1.26B
AVG Volume
1.08K
Trailing/Forward PE
-13.06/-
PEG ratio
-0.58
Dividend Yield
-
Next Earnings Date
2027-03-30
Primary Exchange
Other OTCUS
Revenue (CNY)
020M40M60M21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Net Income (CNY)
-400M-300M-200M-100M021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Operating Income (CNY)
-400M-300M-200M-100M021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
EBITDA (CNY)
-400M-300M-200M-100M021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Cash Flows (CNY)
-300M-200M-100M021 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
EPS (CNY)
-0.4-0.3-0.2-0.1-021 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Expenses (CNY)
0100M200M300M400MR&DSG&ACapex21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Cash & Debt (CNY)
01B2B3BCashShort Term Debt21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Debt ratios
024621 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Margins
-2000%-1500%-1000%-500%0%500%20 Q421 Q221 Q422 Q222 Q423 Q223 Q424 Q425 Q225 Q4
Return on Capital
-15%-10%-5%0%21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Shares Outstanding
0500M1B1.5B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Book Value Per Share (CNY)
012321 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Total Assets (CNY)
01B2B3B21 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q2
Free Cash Flow Yield
-50%-40%-30%-20%-10%0%med -7.2%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Sales
0200040006000med 430.03Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Book
0246810med 4.5Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Ascletis Pharma Inc.
ASCLF
Stockpicker

Video analysis: ASCLF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ASCLF

Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

prnewswire.com · 23 Jun 2026

Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.